Mariangela Manzoni
Overview
Explore the profile of Mariangela Manzoni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
177
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Petrelli F, Antista M, Dottorini L, Russo A, Arru M, Invernizzi R, et al.
Heliyon
. 2024 Sep;
10(17):e36497.
PMID: 39263130
Introduction: The molecular profile of colorectal cancer (CRC) plays a crucial role in understanding patient prognosis and treatment response. Within CRC, a distinct subgroup can be identified by the presence...
2.
Di Cosimo S, Tagliaferri B, Generali D, Giudici F, Agustoni F, Bernardo A, et al.
Cancers (Basel)
. 2021 Apr;
13(6).
PMID: 33809465
Cancer patients may be at high risk of infection and poor outcomes related to SARS-CoV-2. Analyzing their prognosis, examining the effects of baseline characteristics and systemic anti-cancer active therapy (SACT)...
3.
Danova M, Comolli G, Manzoni M, Torchio M, Mazzini G
Mol Clin Oncol
. 2016 Jun;
4(6):909-917.
PMID: 27284422
Malignant tumors are characterized by uncontrolled cell growth and metastatic spread, with a pivotal importance of the phenomenon of angiogenesis. For this reason, research has focused on the development of...
4.
Manzoni M, Comolli G, Torchio M, Mazzini G, Danova M
Clin Colorectal Cancer
. 2015 Jan;
14(1):11-7.
PMID: 25591800
Several anticancer therapies have been developed to block angiogenesis, a key mechanism in tumor growth and metastasis. The predominantly cytostatic action of these compounds makes an assessment of their clinical...
5.
Lodola F, Laforenza U, Bonetti E, Lim D, Dragoni S, Bottino C, et al.
PLoS One
. 2012 Oct;
7(9):e42541.
PMID: 23049731
Background: Endothelial progenitor cells (EPCs) may be recruited from bone marrow to sustain tumor vascularisation and promote the metastatic switch. Understanding the molecular mechanisms driving EPC proliferation and tubulogenesis could...
6.
Manzoni M, Mariucci S, Delfanti S, Rovati B, Ronzoni M, Loupakis F, et al.
J Cancer Res Clin Oncol
. 2012 Mar;
138(7):1187-96.
PMID: 22419441
Background: Bevacizumab has shown consistent clinical efficacy in metastatic colorectal cancer (mCRC), but some patients respond better than others. Thus, it is crucial to identify biomarkers that permit the recognition...
7.
Danova M, Delfanti S, Manzoni M, Mariucci S
J Natl Cancer Inst Monogr
. 2011 Nov;
2011(43):75-8.
PMID: 22043046
Breast cancer therapies are in continuous evolution: From surgery to hormonal therapy, from classical and new combined chemotherapies to emerging targeted agents of recent introduction to the clinic. The attempt...
8.
Loupakis F, Ruzzo A, Salvatore L, Cremolini C, Masi G, Frumento P, et al.
BMC Cancer
. 2011 Jun;
11:247.
PMID: 21669012
Background: Molecular predictors of bevacizumab efficacy in colorectal cancer have not been identified yet. Specific VEGF polymorphisms may affect gene transcription and therefore indirectly influence the efficacy of bevacizumab. Methods:...
9.
Collova E, Rovati B, Grasso D, Bencardino K, Manzoni M, Danova M
Mol Med Rep
. 2011 Apr;
2(1):85-8.
PMID: 21475795
The aim of this study was to evaluate the effect of dose-dense adjuvant chemotherapy regimens with peg-filgrastim support on the phenotype of peripheral blood leukocytes in breast cancer patients. We...
10.
Mariucci S, Rovati B, Manzoni M, Della Porta M, Comolli G, Delfanti S, et al.
Clin Exp Med
. 2010 Dec;
11(4):199-210.
PMID: 21161672
Patients with cancer show variable levels of immunosuppression at the time of the presentation, and cytotoxic antineoplastic therapy is the primary contributor to the clinical immunodeficiency often observed during the...